Aegis FLEX Testing

Aegis provides continuity of care through Aegis FLEX, its innovative and adaptable response to the COVID-19 pandemic

Our Response to the COVID-19 Pandemic

Aegis remains fully operational and can support customers with unique solutions during these times. Amidst current complexities of patient care caused by the COVID-19 outbreak, it is important to remember that urine and oral fluid medication monitoring options remain available to providers.

Introducing Aegis FLEXTM - flexible testing solutions that provide safe alternatives to in-clinic testing:

  • Drive-up Collections
    Aegis offers drive-up collections outside of a clinic for safe, continuous care.
    Contact your Regional Sales Manager or 800.533.7052 for more information.

  • Mobile Testing
    Aegis offers mobile specimen collection performed at a patients home.
    Contact your Regional Sales Manager or 800.533.7052 for more information.

  • Remote Oral Fluid Collections
    Aegis offers two options for remote telemedicine oral fluid sample collections. Learn more
  1. Bulletin

    Bulletin

    The Coronavirus Preparedness and Response Supplemental Appropriations Act was signed into law due to expectations that the COVID-19 pandemic will continue into the foreseeable future. Social distancing, hand washing and self-quarantine were instituted in an attempt to contain viral spread. One important additional provision of the Coronavirus Act is the use of telehealth/telemedicine to limit patient and healthcare provider exposure to the virus.

    We have compiled helpful information into an educational resource for providers that treat high risk patients. Click here to download.